Information Provided By: 
Fly News Breaks for December 7, 2015
GERN
Dec 7, 2015 | 09:06 EDT
Piper Jaffray analyst Charles Duncan said his conviction in imetelstat was increased after attending the American Society of Hematology meeting. The activity observed to date in MF and MDS is fully supportive of advancement to later stage trials, Duncan tells investors in a post-meeting note. The analyst raised his price target on Geron shares to $10 from $5 and maintains an Overweight rating on the stock.
News For GERN From the Last 2 Days
GERN
May 1, 2024 | 10:51 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Deciphera Pharmaceuticals... To see the rest of the story go to thefly.com. See Story Here
GERN
Apr 30, 2024 | 04:51 EDT
